Affordable Access

deepdyve-link
Publisher Website

Circulating tumour cells and circulating free nucleic acid as prognostic and predictive biomarkers in colorectal cancer

Authors
  • Lim, S.H.
  • Becker, T.M.
  • Chua, W.
  • Caixeiro, N.J.
  • Ng, W.L.
  • Kienzle, N.
  • Tognela, A.
  • Lumba, S.
  • Rasko, J.E.J.
  • de Souza, P.
  • Spring, K.J.1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
  • 1 Medical Oncology Group
  • 2 Ingham Institute for Applied Medical Research
  • 3 Department of Medical Oncology
  • 4 Liverpool Hospital
  • 5 School of Medicine
  • 6 University of New South Wales
  • 7 South West Sydney Translational Cancer Research Unit
  • 8 Liverpool Clinical School
  • 9 University of Western Sydney
  • 10 Department of Cell and Molecular Therapies
  • 11 Royal Prince Alfred Hospital
  • 12 Gene and Stem Cell Therapy Program
  • 13 Centenary Institute
  • 14 University of Sydney
Type
Published Article
Journal
Cancer Letters
Publisher
Elsevier
Publication Date
Jan 01, 2013
Accepted Date
Dec 13, 2013
Volume
346
Issue
1
Pages
24–33
Identifiers
DOI: 10.1016/j.canlet.2013.12.019
Source
Elsevier
Keywords
License
Unknown

Abstract

The detection of circulating tumour cells or circulating free tumour nucleic acids can potentially guide treatment and inform prognosis in colorectal cancer using minimally invasive “liquid biopsies”. Current literature supports the notion that high circulating tumour cell counts or presence of tumour nucleic acid correlate with inferior clinical outcomes for patients, but they are not yet part of routine clinical care. Future research evolves around the examination of the molecular phenotype of circulating tumour cells. The key unanswered areas include differentiating between circulating tumour cell presence and their proliferative capacity and dormancy, identifying tumour heterogeneity and understanding the epithelial–mesenchymal transition.

Report this publication

Statistics

Seen <100 times